Articles

Doceree Launches Daily Command: A Game-Changer for Pharma Brand Teams

Doceree has unveiled Daily Command, an AI platform designed for pharma brand teams, co-built with industry leaders. This innovation promises to enhance marketing strategies and operational efficiency.

NICE Endorses Imfinzi for Stomach Cancer: Regulatory Insights

NICE has recently endorsed Imfinzi for perioperative use in stomach cancer, just 17 days post-UK approval. This article analyzes the regulatory updates and their implications.

Eisai's Leqembi Sales Forecast: A Step Toward Blockbuster Status

Eisai's Leqembi sales are projected to reach $900M, indicating a significant shift in the market. This article explores the implications for pharmaceutical stakeholders.

Why Pharma Isn’t the First Voice in the Room: Insights and Implications

This article delves into the reasons behind pharma's delayed voice in critical discussions and its impact on the industry landscape.

The Case for Direct-to-Patient: Execution Challenges Ahead

This article discusses the clear case for direct-to-patient strategies in the pharmaceutical industry and the execution challenges that lie ahead.

Reframing Pharma Commercialization: New Possibilities

This article delves into innovative approaches in pharma commercialization, highlighting key insights and implications for industry stakeholders.

From Reach to Relevance in Pharma Marketing

This article delves into the shift in pharma marketing strategies, emphasizing the importance of relevance over reach. Discover key insights and implications for pharma teams.

Join Our Pharmaceutical Network: Membership Opportunities

Discover the advantages of becoming a member of our pharmaceutical network. Learn how to contact us for membership and the value it brings to your business.

The Oral GLP-1 Tracker: Wegovy Pill Scripts Decline

This article analyzes the recent decline in Wegovy pill prescriptions, its implications for Eli Lilly and Novo Nordisk, and what it means for the pharmaceutical landscape.

Navigating Manufacturing Challenges in Biopharma

As biologics take the lead in biopharma pipelines, manufacturing challenges threaten timely launches. This article explores the implications for industry stakeholders.

Roche's Elevidys Study Launch: Navigating EU Rejection

Roche is set to launch another study for Elevidys following the EMA's rejection. This article analyzes the implications for investors and pharma teams.

Veeva R&D and: Upcoming Event Preview

The Veeva R&D and event is set to take place in Copenhagen from June 15-17, 2026. This preview highlights key takeaways and companies to watch.

Purdue Pharma Shutdown: $7.4B Deal Ends OxyContin Maker's Era

Purdue Pharma, the manufacturer of OxyContin, is ceasing operations as part of a $7.4 billion settlement to address its role in the opioid crisis. This landmark agreement aims to resolve thousands of lawsuits and redirect company assets towards addiction treatment and prevention.

Orchard Therapeutics OTL-201: Innovation Passport for MPS-IIIA

Orchard Therapeutics has secured an Innovation Passport designation from the MHRA for its investigational gene therapy, OTL-201, targeting MPS-IIIA. This marks a significant step in accelerating development and access for patients with Sanfilippo syndrome type A.

NICE Technology Appraisals: Impact on Market Access for Novel Oncology Drugs

This article examines the role of NICE Technology Appraisals in shaping market access strategies for innovative oncology drugs, including Pembrolizumab.

MHRA Post-Brexit Drug Approval: What You Need to Know

Learn about the MHRA's new drug approval process post-Brexit and its impact on the availability of essential medications like Ozempic for diabetes.

CAR-T Cell Therapy Europe: Clinical Trials, Safety & Market Access Insights

Discover the latest insights on CAR-T Cell Therapy in Europe, focusing on clinical trials, safety profiles, and market access for hematologic cancers.

Biosimilar Uptake EU: Market Impact Post-Patent Expirations & HTA Regulation

This article examines how biosimilar adoption in the EU is reshaping the market landscape for biologics like Adalimumab after patent expirations and under HTA regulations.

Auvelity FDA Approval: A New MDD Treatment Option

The FDA has approved Auvelity, a novel oral therapy from Axsome Therapeutics, for the treatment of major depressive disorder (MDD). This marks a significant advancement in MDD treatment options.

EU Pharmaceutical Legislation Reform: Impact on Orphan Drug Market Exclusivity

This article examines how recent EU pharmaceutical legislation reforms could reshape market exclusivity for orphan drugs, affecting access to treatments for rare diseases.